PubMed Health⌕ Search

Biomedical subjects

F Severi

Publications and source records attributed to F Severi.

171 records · Page 10Linked to original sources
PubMedDate not supplied

[Quality in drug administration: review of the therapeutic information system during hospitalization].

The mistakes taking place in therapy administration are regarded as indicative elements of a bad work quality. In order to avoid them and to get the best obtainable quality, the Arezzo USL Administration has established a Work Group charged to ascertain the possible errors and to review the different methods enforced inside the informations therapeutic system. An experimentation has been carried out in sixteen hospital wards, with a subsequent control of the results. In all the U.U.O.O. of Arezzo the "Thermography with direct control" system has been adopted, as it has proved to succeed in eliminating a great deal of the possible risks.

Clinical Pharmacy Information Systems↗
PubMedDate not supplied

MR of the hypothalamic-pituitary axis in Langerhans cell histiocytosis.

PURPOSE: To describe the MR findings in the hypothalamic pituitary area in children with Langerhans cell histiocytosis and to define those MR alterations especially associated with the risk of developing diabetes insipidus. METHODS: The hypothalamic-neurohypophyseal axis was studied by sagittal and coronal 1.5 T1-weighted MR imaging in 14 children with Langerhans cell histiocytosis (five with diabetes insipidus) and in 28 low-stature controls, ages 6-14 years. RESULTS: The pituitary stalk was thicker in seven/14 patients (three with diabetes insipidus) than in controls (P less than .05). Bright posterior pituitary signal was undetectable in children with diabetes insipidus and in one/9 without diabetes insipidus. CONCLUSIONS: Thickening of the hypothalamus and/or the pituitary stalk in the absence of the posterior pituitary bright signal is seen in children with Langerhans cell histiocytosis with overt diabetes insipidus. Those Langerhans cell histiocytosis patients without diabetes insipidus but showing thickened stalk with or without posterior pituitary bright signal could be at high risk to develop diabetes insipidus.

Adolescent↗
PubMedDate not supplied

Recombinant human granulocyte-macrophage colony stimulating factor (rHuGM-CSF) in cyclic neutropenia.

We describe the case of a 12-year-old boy affected by cyclic neutropenia, at high risk of developing life-threatening infections, treated with recombinant human granulocyte-macrophage colony stimulating factor (rHuGM-CSF). The drug was effective in reducing the severity of neutropenia and infectious complications in our patient. It was administered for brief periods of time, in contrast to the daily continuous administration reported for rHuG-CSF. Therefore, more extensive studies must be performed to identify the most effective time schedule for the drug. In vitro studies of hemopoietic progenitor cells were useful, in this case, to predict treatment response.

Child↗
PubMedDate not supplied

[Bone marrow transplantation in the treatment of severe aplastic anemia].

Bone marrow transplantation (BMT) in patient affected by severe aplastic anemia (SAA), is successful in 70-80% of cases, when performed with HLA identical brother or syngeneic twin as donors, and in 11-45% of cases when performed from aploidentical-identical related or HLA identical unrelated donor. The different conditioning regimens (Cy alone or in combination with TBI) have shown similar results in the long term outcomes. Cyclosporin-A is very effective in avoiding rejection and controlling GVHD.

Anemia, Aplastic↗
PubMedDate not supplied

[Hyperthyroidism in children (author's transl)].

The present paper analyzes the causes, signs and symptoms of hyperthyroidism in children and the problems, complications and results associated with the various therapeutic regimes. Childhood hyperthyroidism is usually due to Grave's disease, an autoimmune thyroid disease. Genetic factors are also involved in its development. The diagnosis and in particular the differential diagnosis with Hashimoto's thyroiditis are discussed. Treatment of Graves' disease is controversial, but medical therapy is commonly accepted as the treatment of choice. Some dosage schedules of antithyroid drugs are considered, and some techniques for predicting remission status and relapse of disease are reported. Both the minor and more serious complications of medical therapy are examined. Careful follow-up for the development of hypothyroidism is advocated, especially in patients treated with radiation or surgery. Autonomous hyperfunctioning thyroid adenoma is rare, but occurs even in childhood, and can degenerate into carcinoma.

Adolescent↗
PubMedDate not supplied

Myelodysplastic syndromes: the pediatric point of view.

Myelodysplastic syndromes (MDS) are clonal disorders of the multipotent hematopoietic stem cell characterized by ineffective hematopoiesis and associated with marrow hypercellularity, increased intramedullary cell death and peripheral cytopenias of varying severity. Patients with myelodysplasia have a propensity (20% to 30% of cases) to undergo transformation into acute myeloid leukemia (AML), and a large body of evidence indicates that MDS represent steps in the multiphasic evolution of AML. Progression of the disease is characterized by expansion of the abnormal clone and inhibition of normal hematopoiesis leading to deterioration of the blood cell count and/or development of AML. MDS are relatively unusual in childhood, representing only 3% of pediatric hematological malignancies, although it has been reported that up to 17% of pediatric AML cases may have a previous myelodysplastic phase. The first systematic attempt at morphological classification of MDS was provided by the French-American-British (FAB) group. However, the FAB classification of MDS is only partially applicable in children. Some variants are extremely rare or absent (refractory anemia with ring sideroblasts and chronic myelomonocytic leukemia), and other peculiar pediatric disorders, represented by juvenile chronic myelogenous leukemia (JCML) and the monosomy 7 syndrome, are not included. Moreover, since there is a partial overlap between pediatric MDS and myeloproliferative disorders and the variants occurring in young children have rather specific features, some confusion still surrounds the nosographical definition of childhood MDS, so that none of the proposed classifications are widely accepted and used. Characteristically, some genetic conditions such as Fanconi's anemia, Shwachman's and Down's syndromes predispose to the development of MDS in childhood. The most common variants of childhood MDS are represented by JCML and the monosomy 7 syndrome, both disorders typically occurring in young children. JCML is characterized by a spontaneous growth of granulocyte-macrophage progenitors that show a striking hypersensitivity to granulocyte-macrophage colony-stimulating factor. Clinical presentation resembles that of some myeloproliferative disorders, with massive organomegaly usually not observed in the classically reported variants of MDS. Clinical features of the monosomy 7 syndrome resemble those observed in JCML and a differential diagnosis between these two entities relies upon the higher percentage of fetal hemoglobin, the more pronounced decrease in platelet count and, in some cases, the lack of the peculiar cytogenetic abnormality in the latter. With the number of children being cured of cancer constantly rising, a significant increase in secondary or chemotherapy-related myelodysplasia is being observed, and these disorders represent a formidable challenge for pediatric hematologists due to their poor response to chemotherapy.(ABSTRACT TRUNCATED AT 400 WORDS)

Child↗